GSK private eye accuses Chinese of trying to force confession; Sandoz asks Mississippi high court to toss Medicaid judgment;

@FiercePharma: Vets and pharma execs gather in DC to trade notes on pets in cancer research. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Valeant said to step up talks on potential $800M deal for Egypt's Amoun. Report | Follow @CarlyHFierce

> Peter Humphrey, who was just released from Chinese prison, said officials there withheld medical treatment to induce him to confess to a role in the GlaxoSmithKline ($GSK) bribery scandal. Report

> Novartis' ($NVS) generics unit Sandoz asked the Mississippi Supreme Court to overturn a $38.2 million judgment in a Medicaid drug-pricing suit. Report

> Bayer HealthCare will halt production at a plant in St. Joseph, MO, next week, after announcing earlier this year that the 120-employee facility would close. Report

> Multinational drugmakers are amping up their over-the-counter drug business in China as provincial governments squeeze prices for prescription drugs. Report

Medical Device News

@FierceMedDev: FDA approves Roche's companion diagnostic for Pfizer's non-small cell lung cancer med. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: HeartWare, hit with its fifth Class 1 recall of 2015, will replace defective blood pump controllers. Report | Follow @VarunSaxena2

@EmilyWFierce: Shire, Sanofi and Bayer have the best public reps in pharma. FiercePharma report | Follow @EmilyWFierce

> After 2014 IPO and recent take-out rumor, medical laser player Lumenis ($LMNS) to be acquired for $510M. Story

> Medtronic ($MDT) buys into Arsenal, gets option to purchase the post-surgical foam startup subsidiary. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Synergy soars on stellar constipation data, rekindling buyout chatter. Article | Follow @FierceBiotech

@JohnCFierce: BioMarin shines as dwarfism drug boosts growth in children. News | Follow @JohnCFierce

@DamianFierce: ICYMI: And hey $AGN's spending $2.1B on $KYTH and its chin-fat-reducing injection. Article | Follow @DamianFierce

> Woodford exits Sanofi ($SNY), doubles down on Circassia in portfolio rejig. More

> BioMarin ($BMRN) shines as dwarfism drug boosts growth in children. News

> Merck KGaA hustling a promising anti-malaria drug into human studies. Article

> Medigene files to raise €50M to hit gas on T-cell R&D programs. Report

Vaccines News

> Merck ($MRK), GSK, Sanofi and Pfizer ($PFE) will vie for crown in tight vaccines race by 2020: Report. More

> When it comes to a MERS vaccine, for Big Pharma, the money's not there yet. More

> Merck, Sanofi granted European Commission thumbs-up on Gardasil 9. Story

> Ebola vaccines left hanging as GSK, Merck, J&J ($JNJ) scramble for trial volunteers. Article

> Move over, India--China can make WHO-approved vaccines, too. Report

CRO News

> Quintiles ($Q) beefs up its risk-based monitoring tech. Report

> Veristat reaches into the Bay Area with new outpost. Item

> AMRI ($AMRI) recruits PerkinElmer ($PKI) to build out a new R&D hub. Article

> GVK inks a deep biotech deal as it rebuilds its reputation. News

> PPD partners up for real-world outcomes research. Story

Pharma Manufacturing News

> Sun purges 18 Ranbaxy execs in integration move. Item

> Geri-Care buiding second plant in Mississippi. More

> Lonza building viral therapies plant in Texas. News

> Thermo Fisher ($TMO) putting $22M into new plant in Scotland. Article

> Ukraine drugmaker opens $40M plant in Kyiv. Report

Pharma Asia News

> A heavier China drives cardio, diabetes and healthcare reforms. Item

> India's Strides-Shasun merger hits roadblock over shareholding structure. More

> China FDA ahead for UCB's Neupro after PhIII Parkinson's results. Story

> Emerging markets, Advair generic the trick as India's Cipla eyes growth. Article

> Researchers say compound stops transmission of malaria parasite in mice. Report

And Finally... England's National Health Service proposed using wearable technology to monitor hospital patients. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.